What are immune checkpoint inhibitors?

Immune checkpoint inhibitors are drugs that help the immune system recognize and attack cancer cells by blocking proteins that prevent immune responses.

How big is the Immune Checkpoint Inhibitors Market?

The global Immune Checkpoint Inhibitors Market size was estimated at USD 47.1 Billion in 2023 and is expected to reach USD 230.3 Billion in 2033.

What is the Immune Checkpoint Inhibitors Market growth?

The global Immune Checkpoint Inhibitors Market is expected to grow at a compound annual growth rate of 17.2%. From 2024 To 2033

Who are the key companies/players in the Immune Checkpoint Inhibitors Market?

Some of the key players in the Immune Checkpoint Inhibitors Markets are AstraZeneca plc, F. Hoffmann-La Roche Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Innovent Biologics, Inc., BeiGene, Ltd., Shanghai Junshi Biosciences Co., Ltd., GlaxoSmithKline plc

Which regions are leading in the Immune Checkpoint Inhibitors market?

In 2023, North America dominated the Immune Checkpoint Inhibitors market, holding a significant 45.7% market share.

What are the key challenges facing the market?

High treatment costs and potential side effects of immune checkpoint inhibitors are key challenges limiting market growth.

What are the expected trends in the immune checkpoint inhibitors market?

Ongoing advancements in cancer immunotherapy and increasing approvals of new immune checkpoint inhibitors are expected to drive market growth.

What role do immune checkpoint inhibitors play in cancer treatment?

They enhance the immune system's ability to detect and destroy cancer cells, providing a critical option for patients with various cancers.

Global Immune Checkpoint Inhibitors Market By Type (CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor) By Disease Indication (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin lymphoma, Others) By End-User (Hospitals, Specialty Clinics, Academic & Research Institutions) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Aug 2024
Report ID: 127673
Number of Pages: 293
Format:

- AstraZeneca Plc Company Profile
- F. Hoffmann-La Roche Ltd.
- Merck KGaA Company Profile
- Regeneron Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company
- Innovent Biologics, Inc.
- BeiGene, Ltd.
- Shanghai Junshi Biosciences Co., Ltd.
- GlaxoSmithKline plc
Settings

Related Reports

Our Clients

Inquiry Before Buying

Report ID 127673
Published Date Aug 2024
Rating
- ★★★★★
  
  ★★★★★
- (91)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $6,000 $3,999 USD / per unit save 24%	Multi User $8,000 $5,999 USD / per unit save 28%	Corporate User $10,000 $6,999 USD / per unit save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 3,999)	Buy Now ($ 5,999)	Buy Now ($ 6,999)